Trial Profile
A Phase II, Multi-Center, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, and Efficacy of Intravenous Antegren (Natalizumab) in Crohn's Disease Subjects Concurrently Receiving Remicade (Infliximab) and Not in Remission
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Jun 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary) ; Infliximab
- Indications Crohn's disease
- Focus Adverse reactions; Therapeutic Use
- Sponsors Elan Pharmaceuticals
- 09 May 2014 New trial record